M&A

M&A

Hab Pharma completes merger with oral formulations developer Signature Phytochemicals

Economic Times  

Mumbai-based Hab Pharma has completed a merger with Dehradun-based Signature Phytochemicals through a slump sale. The consolidated entity reports an estimated annual turnover of Rs.600-Cr. The transaction was finalised in March.Founded in 1991, Hab Pharma markets antibiotics, NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and cardiovascular drugs, while Signature Phytochemical is an oral formulations developer established in 2016. The company plans to use the resources from this merger to achieve a revenue target of Rs.3,000-Cr by 2030 by focusing on off-patent molecules across oncology, autoimmune disorders, chronic conditions, and rare diseases.The merged entity intends to expand its market presence across Latin America, Central Asia, and Southeast Asia. Additionally, the company plans to commission two new manufacturing plants: a sterile facility for prefilled syringes and a fully automated oral solid dosage plant with commercial production expected to commence by August 2026.